Previous 10 | Next 10 |
--Initiated Phase 1/1b clinical trial of NGM438, a LAIR1 antagonist antibody product candidate, as a monotherapy and in combination with KEYTRUDA ® (pembrolizumab) for the treatment of patients with advanced solid tumors-- --Initiated the Phase1b portion of the Phase 1/2 tria...
Royal Gold ( NASDAQ: RGLD ) said on Tuesday it paid $525M to acquire a sliding-scale gross royalty on an area including the Cortez mine and Fourmile development project in Nevada from Rio Tinto's ( NYSE: RIO ) Kennecott Royalty subsidiary. The area in the Cortez ...
Raymond James updated its list of analyst favorite stocks with a swap in the restaurant subsector. Analysts can only have one favorite idea among the stocks they cover rated Strong Buy or Outperform. Ruth's Hospitality Group ( NASDAQ: RUTH ) makes it onto the Analysts Cu...
After winning FDA’s priority review for its lead candidate pegcetacoplan in geographic atrophy (GA) secondary to age-related macular degeneration (AMD), the commercial-stage biotech Apellis Pharmaceuticals ( APLS ) has rallied its rivals targeting the eye disease. Not...
Siobhan Nolan Mangini, CFO of NGM Biopharmaceuticals ( NASDAQ: NGM ) has been appointed to the additional role of President. David J. Woodhouse, Ph.D. will continue to serve as NGM Bio’s Chief Executive Officer. William J. Rieflin, who has served as Executive Ch...
-- William J. Rieflin to transition from Executive Chairman to Chairman of the Board of Directors -- SOUTH SAN FRANCISCO, Calif., June 30, 2022 (GLOBE NEWSWIRE) -- NGM Biopharmaceuticals, Inc. (NGM Bio) (Nasdaq: NGM), a biotechnology company focused on discovering and developing tra...
Gainers: Agile Therapeutics (AGRX) +81%. Kezar Life Sciences (KZR) +75%. Decibel Therapeutics (DBTX) +21%. Sutro Biopharma (STRO) +16%. Bellerophon Therapeutics (BLPH) +11%. Losers: Scholar Rock (SRRK) -11%. NGM Biopharmaceuticals (NGM)...
--NGM621, a monoclonal antibody product candidate engineered to potently inhibit complement C3 for the treatment of patients with geographic atrophy, will be showcased in the fourth of a four-part series titled the “Explorer Series”-- SOUTH SAN FRANCISCO, Calif., Jun...
Results from the phase 2 CATALINA study using NGM621 for the treatment of patients with Geographic Atrophy are expected in the 2nd half of 2022. Results from a phase 1/2 study using NGM707 for the treatment of patients with advanced cancer are expected in the 2nd half of 2022. Res...
The following slide deck was published by NGM Biopharmaceuticals, Inc. in conjunction with this event. For further details see: NGM Biopharmaceuticals (NGM) Investor Presentation - Slideshow
News, Short Squeeze, Breakout and More Instantly...
NGM Biopharmaceuticals Inc. Company Name:
NGM Stock Symbol:
NYSE Market:
NGM Biopharmaceuticals Inc. Website:
SAN FRANCISCO, April 05, 2024 (GLOBE NEWSWIRE) -- NGM Biopharmaceuticals, Inc. (“NGM Bio”) (Nasdaq: NGM), a biotechnology company focused on discovering and developing transformative therapeutics for patients, today announced that Atlas Neon Parent, Inc. (“Parent”), an...
SOUTH SAN FRANCISCO, Calif., March 19, 2024 (GLOBE NEWSWIRE) -- NGM Biopharmaceuticals, Inc. (NGM Bio) (Nasdaq: NGM), a biotechnology company focused on discovering and developing transformative therapeutics for patients, today announced that two abstracts highlighting clinical data from the ongo...
--Enrollment ongoing for patients with microsatellite stability (MSS) colorectal cancer (CRC) in Phase1/2 trial of NGM707, a dual ILT2/ILT4 antagonist antibody product candidate, in combination with KEYTRUDA® (pembrolizumab) with expected completion of enrollment in the second quarter of 202...